A Phase 2 Study of Belantamab Mafodotin in People with Recurrent or Persistent Multiple Myeloma


Full Title

A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)


Researchers are doing this study to learn more about changes in the eyes and vision caused by belantamab mafodotin. This drug works well for treating multiple myeloma. However, it can cause side effects in the front part of the eye (cornea) that may affect vision. It may also cause blurred vision and dry or itchy eyes.

In this study, researchers want to find the best doses and treatment schedules for belantamab mafodotin. They are seeking a dosing regimen that works well, with the least amount of side effects, in people with multiple myeloma that keeps growing even after treatment. Belantamab mafodotin is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that came back or keeps growing after at least three prior regimens of treatment.
  • Have completed prior therapies at least 2 weeks before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please contact Dr. Malin Hultcrantz’s office at 646-608-3741.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID